FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Why Johnson & Johnson’s CEO Welcomes Scrutiny
Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...
Medical News Today9d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
IFLScience13d
FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...
Nasdaq3d
Is Johnson & Johnson Stock a Buy?
Johnson & Johnson's financial results are generally ... a new law in the U.S. that gives Medicare the power to negotiate drug prices. The first round of negotiations will target three of the ...
AOL13d
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
neuroscience leader with the drug’s manufacturer, Johnson & Johnson, said in a news release. “For too long, health care providers have had few options to offer patients much-needed symptom ...